As GLP-1 compounding stares down a wall, telehealth companies pivot to hormones Health experts warn that profits may drive prescription behavior more than medical need

https://www.statnews.com/2025/03/11/telehealth-firms-pivot-from-glp1-weight-loss-drugs-to-hormone-replacement-therapy/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--ALWtv-OluqfkGusOrxJ6SMP8EfVADFPqJ0asg0cwx88AUvos63YNshOsdxLFcbHJVUYmu9EnMrYKygjIh6hFHFjQ0_A&_hsmi=351081588&utm_content=351081588&utm_source=hs_email Telehealth companies say goodbye to weight loss, hello to hormones In the two years since blockbuster weight loss drugs like Ozempic and Wegovy came on the scene, hundreds of businesses have cropped up to meet the surge in demand for these medications, known as GLP-1s. The majority prescribe compounded copies of the drugs — a tenuous business strategy, now that shortages of the branded versions of the medications have come to an end. But STAT’s Katie Palmer reports that, in their place, some businesses are setting their sights on another opportunity in compounding: hormones. Dozens of wellness and direct-to-consumer telehealth companies that offer GLP-1s have started marketing hormone replacement therapy to women in perimenopause and menopause, and testosterone replacement therapy to men. Health experts warn that profits may drive prescription behavior more than medical need. Read more from Katie on the latest trend.